IL323224A - Crystalline form - Google Patents
Crystalline formInfo
- Publication number
- IL323224A IL323224A IL323224A IL32322425A IL323224A IL 323224 A IL323224 A IL 323224A IL 323224 A IL323224 A IL 323224A IL 32322425 A IL32322425 A IL 32322425A IL 323224 A IL323224 A IL 323224A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- crystalline form
- fluoro
- mmol
- ray powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23161547 | 2023-03-13 | ||
| PCT/EP2024/056495 WO2024188999A1 (en) | 2023-03-13 | 2024-03-12 | Crystalline form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL323224A true IL323224A (en) | 2025-11-01 |
Family
ID=85601718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL323224A IL323224A (en) | 2023-03-13 | 2025-09-08 | Crystalline form |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4680340A1 (es) |
| JP (1) | JP2026508943A (es) |
| KR (1) | KR20250155619A (es) |
| CN (1) | CN120917029A (es) |
| AU (1) | AU2024236796A1 (es) |
| CL (1) | CL2025002744A1 (es) |
| IL (1) | IL323224A (es) |
| MX (1) | MX2025010674A (es) |
| WO (1) | WO2024188999A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| WO2026114356A1 (zh) * | 2024-11-29 | 2026-06-04 | 普罗思特(南京)生物科技有限公司 | 含氮杂环化合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4304720A1 (en) * | 2021-03-11 | 2024-01-17 | Mirati Therapeutics, Inc. | Mta-cooperative prmt5 inhibitors |
| US20240368153A1 (en) * | 2021-07-02 | 2024-11-07 | Mirati Therapeutics, Inc. | Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors |
| EP4402143A1 (en) | 2021-09-13 | 2024-07-24 | Astrazeneca AB | Spirocyclic compounds |
-
2024
- 2024-03-12 JP JP2025553773A patent/JP2026508943A/ja active Pending
- 2024-03-12 CN CN202480017739.5A patent/CN120917029A/zh active Pending
- 2024-03-12 KR KR1020257033631A patent/KR20250155619A/ko active Pending
- 2024-03-12 EP EP24709774.4A patent/EP4680340A1/en active Pending
- 2024-03-12 WO PCT/EP2024/056495 patent/WO2024188999A1/en not_active Ceased
- 2024-03-12 AU AU2024236796A patent/AU2024236796A1/en active Pending
-
2025
- 2025-09-08 IL IL323224A patent/IL323224A/en unknown
- 2025-09-10 MX MX2025010674A patent/MX2025010674A/es unknown
- 2025-09-10 CL CL2025002744A patent/CL2025002744A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2025002744A1 (es) | 2026-01-02 |
| KR20250155619A (ko) | 2025-10-30 |
| MX2025010674A (es) | 2025-10-01 |
| AU2024236796A1 (en) | 2025-10-30 |
| WO2024188999A1 (en) | 2024-09-19 |
| JP2026508943A (ja) | 2026-03-13 |
| EP4680340A1 (en) | 2026-01-21 |
| CN120917029A (zh) | 2025-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104411700B (zh) | 4-[5-(吡啶-4-基)-1h-1,2,4-三唑-3-基]吡啶-2-腈的多晶型及其制造方法 | |
| JP7406674B2 (ja) | スピロ環化合物 | |
| WO2024188999A1 (en) | Crystalline form | |
| EP3183253B1 (en) | Salt of (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid | |
| CN110678178A (zh) | Mk2抑制剂的形式和组合物 | |
| JP2025538506A (ja) | がんの治療のための縮合ピリジンの固体形態 | |
| TW202233607A (zh) | Kras g12c抑制劑化合物之新結晶形式 | |
| CN120882710A (zh) | 氮杂环丁烷parp1抑制剂的结晶形式 | |
| CN114075199A (zh) | Jak抑制剂化合物及其用途 | |
| WO2014159353A1 (en) | Solid state forms of vemurafenib hydrochloride | |
| JP7068402B2 (ja) | チアゾール誘導体の製造方法 | |
| CN114401720A (zh) | 多酪氨酸激酶抑制剂的晶型、制备方法及其用途 | |
| EP4293021A1 (en) | Salt of nitrogen-containing fused heterocyclic compound or crystal form thereof, and preparation method therefor, pharmaceutical composition thereof, and use thereof | |
| CN111484488A (zh) | 一种b-raf激酶二聚体抑制剂的稳定结晶形式a | |
| KR102858471B1 (ko) | Lta4h 저해제의 결정질 형태 | |
| JP2024520920A (ja) | イミダゾリジノン類化合物の多形体、調製方法及びその使用 | |
| CA2596754C (en) | Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its uses for the treatment of inflammatory, autoimmune and proliferative diseases and disorders | |
| EP4467536A1 (en) | Crystalline form of sulfur-containing isoindoline derivative | |
| EP4714947A1 (en) | Crystal form of pyrimido azacyclo compound, and preparation method therefor and use thereof | |
| CN109516976B (zh) | 取代嘧啶类pi3k抑制剂甲磺酸盐的晶型及其制备方法 | |
| KR20260069720A (ko) | 트리아졸로피리미디논 유도체의 결정형 | |
| HK40061484A (en) | Jak inhibitor compound and use thereof | |
| TW202606690A (zh) | 吡啶并吡唑衍生物的晶型物、藥物組合物及其用途 | |
| WO2025229146A1 (en) | Crystalline form of a pyridazine nlrp3 inhibitor | |
| CA3246483A1 (en) | Crystal form of a fused ring derivative, a prepartion method therefor and use thereof |